WO2008027912A3 - Prediction of an agent's or agents' activity across different cells and tissue types - Google Patents

Prediction of an agent's or agents' activity across different cells and tissue types Download PDF

Info

Publication number
WO2008027912A3
WO2008027912A3 PCT/US2007/077022 US2007077022W WO2008027912A3 WO 2008027912 A3 WO2008027912 A3 WO 2008027912A3 US 2007077022 W US2007077022 W US 2007077022W WO 2008027912 A3 WO2008027912 A3 WO 2008027912A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
agents
patient
activity
prediction
Prior art date
Application number
PCT/US2007/077022
Other languages
French (fr)
Other versions
WO2008027912A2 (en
Inventor
Dan Theodorescu
Jae Kyun Lee
Original Assignee
Dan Theodorescu
Jae Kyun Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dan Theodorescu, Jae Kyun Lee filed Critical Dan Theodorescu
Priority to EP07841494A priority Critical patent/EP2062181A2/en
Publication of WO2008027912A2 publication Critical patent/WO2008027912A2/en
Publication of WO2008027912A3 publication Critical patent/WO2008027912A3/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Abstract

The present invention relates to a novel algorithm that uses molecular profile signatures to extrapolate the physiological processes of one type of cell set (e.g., cell line, tissue, normal or diseased) to predict the activity of an agent or agents against another type of cell set that has never been exposed to the agent in question (drug efficacy prediction). The novel algorithm also allows one to predict the therapeutic response of a patient to a therapeutic regimen even though the patient (or patients) may have never been exposed to that agent before, thereby allowing for selecting a therapeutic agent or combination of agents that would best suit the patient (i.e., personalized medicine). The present invention also relates to methods of using the agents identified by the novel algorithm to treat a variety of diseases, including cancer.
PCT/US2007/077022 2006-08-28 2007-08-28 Prediction of an agent's or agents' activity across different cells and tissue types WO2008027912A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07841494A EP2062181A2 (en) 2006-08-28 2007-08-28 Prediction of an agent's or agents' activity across different cells and tissue types

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84064406P 2006-08-28 2006-08-28
US60/840,644 2006-08-28
US84083406P 2006-11-22 2006-11-22
US60/840,834 2006-11-22

Publications (2)

Publication Number Publication Date
WO2008027912A2 WO2008027912A2 (en) 2008-03-06
WO2008027912A3 true WO2008027912A3 (en) 2008-10-09

Family

ID=39136803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/077022 WO2008027912A2 (en) 2006-08-28 2007-08-28 Prediction of an agent's or agents' activity across different cells and tissue types

Country Status (2)

Country Link
EP (1) EP2062181A2 (en)
WO (1) WO2008027912A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171184A (en) * 2008-08-05 2011-08-31 开普敦大学 Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells
WO2010083385A2 (en) * 2009-01-15 2010-07-22 The General Hospital Corporation Compounds for reducing drug resistance and uses thereof
US8051947B2 (en) * 2009-03-12 2011-11-08 E.I. Du Pont De Nemours And Company Energy absorbing thermoplastic elastomer
EP2433232A1 (en) * 2009-05-20 2012-03-28 Koninklijke Philips Electronics N.V. Biomarkers based on sets of molecular signatures
EP2461806A4 (en) 2009-07-31 2012-12-26 Us Health Antiangiogenic small molecules and methods of use
JP2013516410A (en) * 2009-12-31 2013-05-13 コーニング インコーポレイテッド Molecules related to hERG ion channel and use thereof
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
CN105556523B (en) * 2013-05-28 2017-07-11 凡弗3基因组有限公司 PARADIGM medicine response networks
AU2014316783A1 (en) * 2013-09-09 2016-04-28 Glionova Ab Compounds and use for treating cancer
AU2014384291B2 (en) 2014-02-25 2017-12-21 Ecolab Usa Inc. Sanitary cleaner
CN104610207B (en) * 2014-07-15 2017-05-10 云南西力生物技术股份有限公司 Gardenia sootepensis gardenin A, preparation method and medicinal application thereof
WO2016210289A1 (en) * 2015-06-24 2016-12-29 Duke University Chemical modulators of signaling pathways and therapeutic use
WO2017017004A1 (en) * 2015-07-24 2017-02-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Substituted hydrophobic benzene sulfonamide thiazole compounds for use in treating cancer
GB201514018D0 (en) * 2015-08-07 2015-09-23 Arnér Elias S J And United States Of America Asrepresented By The Sec Dep Of Health And Human Servic Novel tricyclic compounds and their use in the treatment of cancer
US11749383B2 (en) 2016-03-28 2023-09-05 The Regents Of The University Of California Methods and systems of predicting agent induced effects in silico
US10510010B1 (en) 2017-10-11 2019-12-17 Liquid Biosciences, Inc. Methods for automatically generating accurate models in reduced time
WO2019074504A1 (en) * 2017-10-11 2019-04-18 Liquid Biosciences, Inc. Methods for automatically generating accurate models in reduced time
CN111153948B (en) * 2018-11-07 2022-10-18 华北制药集团新药研究开发有限责任公司 Kinetocystins compound and application thereof
CN112461915A (en) * 2020-12-08 2021-03-09 杭州汇健科技有限公司 Method for characteristic molecule screening, drug sensitivity degree detection and cell subtype detection related to drug sensitivity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042681A1 (en) * 2000-10-03 2002-04-11 International Business Machines Corporation Characterization of phenotypes by gene expression patterns and classification of samples based thereon
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US20020042681A1 (en) * 2000-10-03 2002-04-11 International Business Machines Corporation Characterization of phenotypes by gene expression patterns and classification of samples based thereon

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ISHIKAWA ET AL.: "Expression of MDA-7/IL-24 and Its Clinical Significance in Resected Non-Small Cell Lung Cancer", CLINICAL CANCER RESEARCH, vol. 11, pages 1198 - 1202, XP008131333 *
MA ET AL.: "Predicting Cancer Drug Response by Proteomic Profiling", CLINICAL CANCER RESEARCH, vol. 12, no. 15, 1 August 2006 (2006-08-01), pages 4583 - 4589, XP003025615 *
PAL ET AL.: "Boolean relationships among genes responsive to ionizing radiation in the NCI 60 ACDS", BIOINFORMATICS, vol. 21, no. 8, 2005, pages 1542 - 1549, XP008131353 *

Also Published As

Publication number Publication date
WO2008027912A2 (en) 2008-03-06
EP2062181A2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
WO2008027912A3 (en) Prediction of an agent's or agents' activity across different cells and tissue types
NO20074999L (en) Method and preparation for the treatment of peripheral vascular diseases
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
EP3150204A3 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
EP1558220A4 (en) Oral compositions for treatment of diseases
WO2007146229A3 (en) Markers associated with arteriovascular events and methods of use thereof
RS20150135A1 (en) Treatment with anti-vegf antibodies
BRPI0519656A2 (en) combination therapy comprising telmisartan and hydrochlorothiazide
WO2005027839A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP2331095A4 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2007097797A3 (en) Positioning system for manipulating a channel within a medical device
WO2006048450A3 (en) Peptides for use in the treating obesity
CY1112184T1 (en) PYRIDOXAMINE FOR USE IN TREATMENT OF DIABETIC Nephropathy in Type II Diabetes
WO2003082078A3 (en) Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
WO2006048452A3 (en) Peptides for use in treating of obesity
WO2007011955A3 (en) Drug-containing implants and methods of use thereof
WO2008060618A3 (en) Use of genetic determinants in cardiovascular risk assessment
WO2007145992A3 (en) Genetic basis of treatment response in depression patients
MXPA05008461A (en) Kit for applying drug coating to a medical device in surgeon room.
WO2007092427A3 (en) Treatment of endotoxemia using endotoxin neutralizing agents
BRPI0610780A2 (en) disintegrating tablet pharmaceutical formulation, and methods for treating a patient in need of olanzapine treatment, and for producing the tablet pharmaceutical formulation
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2007025229A3 (en) Compositions and their uses directed to hsp27

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07841494

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007841494

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)